SOUTH SAN FRANCISCO, June 1, 2016 – Sutro Biopharma today announced the appointment of Dr. Shabbir T. Anik to the newly-created position of chief technical operations officer. Dr. Anik brings over 30 years of experience in pharmaceutical technology, drug development, manufacturing operations and strategic alliance-building to Sutro as it advances its late-stage preclinical and emerging clinical pipeline.

“As we accelerate our antibody drug conjugate and immuno-oncology pipelines into clinical development, Shabbir’s expertise and proven track record of strategic business acumen will prove invaluable,” Sutro CEO William Newell said. “Shabbir’s deep manufacturing experience will help us launch our proprietary cell-free manufacturing plant and propel Sutro toward being a fully integrated biopharmaceutical company.”

Dr. Anik most recently served as senior vice president of technical operations at Onyx Pharmaceuticals, with responsibility for all chemistry, manufacturing and control activities from early development through commercial launch. Dr. Anik’s team at Onyx developed a commercial supply chain for the launch and ongoing commercialization of Kyprolis® for the treatment of multiple myeloma. Prior to joining Onyx, Dr. Anik was president and CEO of Althea Technologies, a contract developer and manufacturer that he positioned as one of few protein biologics companies to provide fully integrated services from cell line to commercial finished product. Dr. Anik also previously served as president of global pharmaceutical development services and chief scientific officer of Patheon, where he acquired technologies through strategic alliances and built a product development organization of 600 staff in North America and Europe.

Dr. Anik earned a PhD in pharmaceutical sciences from the University of Wisconsin at Madison and an MBA from Santa Clara University.

About Sutro Biopharma

Sutro Biopharma, Inc., located in South San Francisco, develops best-in-class antibody drug conjugate (ADC) and multi-specific antibody-based therapeutics for cancer therapy, including immuno-oncology therapies. Sutro’s discovery and development efforts are driven by our proprietary Xpress CF+™ platforms, a biochemical synthesis system that enables rapid and systematic evaluation of protein structure-activity relationships, as well as rapid and predictable scalability for manufacturing in Sutro’s cGMP facility. In addition to developing its own drug candidate pipeline, which is focused on mono- and bi-specific ADCs, Sutro Biopharma is collaborating with select pharmaceutical and biotech companies to discover and develop novel therapeutics.

Media Contacts:

David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com

Amiad Finkelthal
Russo Partners
(646) 942-5626
amiad.finkelthal@russopartnersllc.com